Procyanidin Composition for Broncho-constrictive Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for broncho-constrictive conditions like Allergic Rhinitis, Asthma, and COPD are inadequate in effectively managing symptoms and preventing progression, with existing medications having adverse effects and limited efficacy.
Innovation Solution
A composition comprising pentameric type A procyanidin, trimeric procyanidin, and tetrameric procyanidin, optionally with pharmaceutical excipients, is administered to manage broncho-constrictive conditions, formulated into various dosage forms and administered at specific concentrations to achieve therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications (bronchodilators and inhaled steroids) are used to treat broncho-constrictive conditions, then airway opening and inflammation reduction are achieved, but adverse cardiovascular side effects and limited long-term efficacy occur
Solution Approach 1:
The patent extracts and utilizes specific procyanidin oligomers (pentameric type A, trimeric, and tetrameric) from natural plant sources to treat broncho-constrictive conditions. This extraction of specific bioactive compounds replaces conventional medications with natural alternatives that achieve therapeutic effects without the harmful cardiovascular side effects associated with synthetic bronchodilators and steroids.
Solution Approach 2:
The patent employs procyanidin oligomers derived from readily available plant materials (grape seeds, green tea, cocoa) as a cost-effective therapeutic alternative. These natural compounds provide effective symptom management without the long-term safety concerns and high costs associated with conventional pharmaceutical treatments, offering a sustainable and accessible treatment option.
2Object-affected harmful factors
If COX-2 inhibition is used to reduce inflammation, then anti-inflammatory effects are achieved, but bronchoprotective prostaglandin E2 secretion is inhibited and cardiovascular side effects occur
Solution Approach 1:
The patent converts the potential harm of inflammation into a benefit by using procyanidin oligomers that modulate the inflammatory response rather than simply suppressing it. These compounds reduce bronchiolar inflammation through multiple pathways while simultaneously maintaining or enhancing bronchoprotective mechanisms, thereby converting the harmful inflammatory process into a controlled, beneficial therapeutic response without the side effects of COX-2 inhibition.
3Ease of operation
If current treatments are used for broncho-constrictive conditions, then some symptom relief is achieved, but quality of life improvement is limited and disease progression is not prevented
Solution Approach 1:
The patent employs procyanidin oligomers that act preliminarily to prevent disease progression by addressing underlying inflammatory and oxidative stress mechanisms before they lead to further airway damage. These compounds provide not only symptom relief but also preventive action that slows or stops disease progression, offering a comprehensive approach that conventional treatments fail to provide.
Data Source
AI summary
The present disclosure is in relation to the use of a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutical excipient(s), in management of broncho- constrictive conditions such as Allergic Pvhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).